

## **DIVI'S LABORATORIES LIMITED**

**CIN No.L24110TG1990PLC011854**

**1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli  
Hyderabad – 500 032 Telangana, India**

**Phone: 91-40-23786300 email: kishore@divislabs.com**

**PRESS RELEASE dated 27<sup>th</sup> January, 2018**

### **Divi's Labs earns PAT of Rs.225 crores in Q3/FY18**

#### **Quarter ended 31<sup>st</sup> December, 2017**

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.225 crores on a total income of Rs.1055 crores, on a stand-alone basis, for the quarter ended 31<sup>st</sup> December, 2017. For the corresponding quarter of the last year, the company earned a PAT of Rs. 268 crores on a total income of Rs. 998 crores.

During the quarter, there was a forex loss of Rs.16 crores as against a forex gain of Rs. 0.65 crores during the corresponding quarter last year.

#### **9-months ended 31<sup>st</sup> December, 2017**

For the 9-month period ended 31<sup>st</sup> December, 2017, the company earned a total income of Rs. 2814 crores as compared to Rs. 3054 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs. 823 crores as against a PBT of Rs. 1038 crores for the previous period. PAT for the current 9-months is Rs. 608 crores as against Rs. 794 crores.

Revenue in the first half of the current year was impacted due to the Import Alert issued by US-FDA, which has since been resolved.

#### **Update on US-FDA inspection**

The company's Unit-II at Visakhapatnam was inspected by the US-FDA from 11<sup>th</sup> September 2017 to 19<sup>th</sup> September 2017. US-FDA has issued Establishment Inspection Report (EIR) for the same.

